Ocular Therapeutix, Inc. (OCUL) financial statements (2021 and earlier)
Company profile
| Business Address |
24 CROSBY DRIVE BEDFORD, MA 01730 |
| State of Incorp. | DE |
| Fiscal Year End | December 31 |
| SIC | 2834 - Pharmaceutical Preparations (benchmarking) |
| More info | Complete financial analysis Financial benchmarking |
Balance sheet (Statement of financial position) ($ in millions)
| 12/31/2020 | 12/31/2019 | 12/31/2018 | 12/31/2017 | 12/31/2016 | 12/31/2015 | 12/31/2014 | |||
|---|---|---|---|---|---|---|---|---|---|
| ASSETS | |||||||||
| Current Assets | |||||||||
| Cash, cash equivalents, and short-term investments | 228 | 54 | 54 | 42 | 68 | 105 | 75 | ||
| Cash and cash equivalents | 228 | 54 | 54 | 42 | 33 | 31 | 37 | ||
| Short-term investments | 35 | 74 | 37 | ||||||
| Receivables | 12 | 3 | 0 | 0 | 0 | 0 | 0 | ||
| Inventory, net of allowances, customer advances and progress billings | 1 | 1 | 0 | 0 | 0 | 0 | 0 | ||
| Inventory | 1 | 1 | 0 | 0 | 0 | 0 | 0 | ||
| Deferred costs | 0 | ||||||||
| Other undisclosed current assets | 5 | 2 | 2 | 1 | 1 | 2 | 1 | ||
| Total current assets: | 246 | 60 | 56 | 43 | 70 | 107 | 76 | ||
| Noncurrent Assets | |||||||||
| Operating lease, right-of-use asset | 6 | 7 | ✕ | ✕ | ✕ | ✕ | ✕ | ||
| Property, plant and equipment | 8 | 10 | 10 | 10 | 3 | 3 | 2 | ||
| Restricted cash and investments | 2 | 2 | 7 | 2 | 2 | 0 | 0 | ||
| Total noncurrent assets: | 16 | 19 | 17 | 12 | 5 | 3 | 2 | ||
| TOTAL ASSETS: | 262 | 79 | 73 | 55 | 75 | 110 | 78 | ||
| LIABILITIES AND EQUITY | |||||||||
| Liabilities | |||||||||
| Current Liabilities | |||||||||
| Accounts payable and accrued liabilities | 17 | 11 | 9 | 8 | 7 | 5 | 6 | ||
| Accounts payable | 3 | 3 | 3 | 4 | 2 | 2 | 1 | ||
| Accrued liabilities | 14 | 8 | 6 | 4 | 5 | 3 | 3 | ||
| Employee-related liabilities | 1 | ||||||||
| Debt | 8 | 1 | 6 | 2 | 1 | ||||
| Deferred revenue and credits | ✕ | ✕ | ✕ | 0 | 0 | ||||
| Other undisclosed current liabilities | 1 | (1) | |||||||
| Total current liabilities: | 27 | 12 | 9 | 13 | 8 | 5 | 6 | ||
| Noncurrent Liabilities | |||||||||
| Long-term debt and lease obligation | 49 | 58 | 25 | 12 | 14 | 15 | 14 | ||
| Long-term debt, excluding current maturities | 41 | 49 | 25 | 12 | 14 | 15 | 14 | ||
| Operating lease, liability | 8 | 9 | ✕ | ✕ | ✕ | ✕ | ✕ | ||
| Liabilities, other than long-term debt | 110 | 12 | 3 | 3 | 1 | 0 | 0 | ||
| Deferred revenue and credits | ✕ | ✕ | 3 | 3 | 1 | 0 | 0 | ||
| Deferred revenue | 12 | ✕ | ✕ | ✕ | ✕ | ✕ | |||
| Derivative instruments and hedges, liabilities | 98 | 12 | |||||||
| Total noncurrent liabilities: | 159 | 70 | 28 | 16 | 15 | 15 | 14 | ||
| Total liabilities: | 186 | 82 | 37 | 29 | 23 | 21 | 19 | ||
| Stockholders' equity | |||||||||
| Stockholders' equity attributable to parent | 76 | (4) | 36 | 26 | 52 | 90 | 59 | ||
| Common stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||
| Additional paid in capital | 615 | 380 | 333 | 263 | 226 | 219 | 148 | ||
| Accumulated other comprehensive loss | (0) | (0) | |||||||
| Accumulated deficit | (539) | (384) | (297) | (237) | (174) | (129) | (89) | ||
| Total stockholders' equity: | 76 | (4) | 36 | 26 | 52 | 90 | 59 | ||
| TOTAL LIABILITIES AND EQUITY: | 262 | 79 | 73 | 55 | 75 | 110 | 78 | ||
Income statement (P&L) ($ in millions)
| 12/31/2020 | 12/31/2019 | 12/31/2018 | 12/31/2017 | 12/31/2016 | 12/31/2015 | 12/31/2014 | ||
|---|---|---|---|---|---|---|---|---|
| Revenues | 17 | 4 | 2 | 2 | 2 | 2 | 1 | |
| Revenue, net | ✕ | ✕ | ✕ | 2 | 2 | 2 | 1 | |
| Cost of revenue | (2) | (2) | (0) | (0) | (0) | (0) | (0) | |
| Cost of goods and services sold | (2) | (2) | (0) | (0) | (0) | (0) | ||
| Gross profit: | 15 | 2 | 2 | 1 | 1 | 1 | 1 | |
| Operating expenses | (78) | (88) | (61) | (63) | (45) | (40) | (28) | |
| Other undisclosed operating income | 0 | 0 | ||||||
| Operating loss: | (63) | (86) | (59) | (62) | (43) | (38) | (27) | |
| Nonoperating expense | (93) | (1) | (1) | (1) | (1) | (2) | (2) | |
| Investment income, nonoperating | 0 | 1 | 1 | 0 | 0 | 0 | 0 | |
| Other nonoperating income (expense) | (0) | 0 | (0) | 0 | (0) | |||
| Interest and debt expense | (7) | (6) | (2) | (2) | (2) | (2) | (1) | |
| Loss before gain (loss) on sale of properties: | (162) | (92) | (62) | (65) | (46) | (41) | (30) | |
| Other undisclosed net income | 7 | 179 | 2 | |||||
| Net income (loss): | (156) | 86 | (60) | (65) | (46) | (41) | (30) | |
| Other undisclosed net income (loss) attributable to parent | (173) | 2 | 2 | 2 | 1 | |||
| Net loss attributable to parent: | (156) | (86) | (60) | (63) | (45) | (40) | (29) | |
| Preferred stock dividends and other adjustments | (0) | |||||||
| Net loss available to common stockholders, diluted: | (156) | (86) | (60) | (63) | (45) | (40) | (29) | |
Comprehensive Income ($ in millions)
| 12/31/2020 | 12/31/2019 | 12/31/2018 | 12/31/2017 | 12/31/2016 | 12/31/2015 | 12/31/2014 | ||
|---|---|---|---|---|---|---|---|---|
| Net income (loss): | (156) | 86 | (60) | (65) | (46) | (41) | (30) | |
| Comprehensive income (loss): | (156) | 86 | (60) | (65) | (46) | (41) | (30) | |
| Other undisclosed comprehensive income (loss), net of tax, attributable to parent | (173) | 2 | 2 | 2 | ||||
| Comprehensive loss, net of tax, attributable to parent: | (156) | (86) | (60) | (63) | (45) | (40) | (30) | |
Statements sources
The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.